Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.03.23.644781

Human Fcγ-receptors selectively respond to C-reactive protein (CRP) isoforms

Abstract

The pentameric C-reactive protein (pCRP), an acute-phase protein, binds to lysophosphatidylcholine (LPC) displayed on the surface of dying cells and microorganisms to activate the complement system and to opsonize immune cells via Fc{gamma}-receptors (Fc{gamma}Rs). Members of the Fc{gamma}R family are characterized by the recognition of the Fc part of IgG antibodies. We utilized a mouse thymoma BW5147 reporter cell panel stably expressing chimeric human Fc{gamma}R-CD3{zeta}-chain receptors to define the molecular requirements for Fc{gamma}R crosslinking by C-reactive protein (CRP). Applying this approach, we show a robust activation of CD64/Fc{gamma}RI and CD32a/Fc{gamma}RIIa by immobilized CRP isoforms as well as triggering of inhibitory CD32b/Fc{gamma}RIIb. Of note, activation of Fc{gamma}RIIa was restricted to the 131R allelic variant but not observed with 131H. In contrast, Fc{gamma}RIII isoforms CD16aF, CD16aV and CD16b were not activated by pCRP, although binding of CRP isoforms to Fc{gamma}RIII was detectable. Activation of Fc{gamma}Rs by free pCRP in solution phase was considerably lower than with immobilized pCRP on hydrophilic plastic surfaces and readily abolished by IgG at serum level concentrations, whereas it was enhanced by the addition of streptococci. The types of Fc{gamma}Rs mainly responding to pCRP in solution phase (CD64/Fc{gamma}RI and CD32aR/Fc{gamma}RIIaR) clearly differed from Fc{gamma}Rs responding to soluble multimeric IgG complexes (i.e., CD16aV/Fc{gamma}RIIIaV and CD32aH/Fc{gamma}RIIaH). Compared to pCRP, monomeric CRP (mCRP) showed lower levels of activation in those selective Fc{gamma}Rs. Fc{gamma}R activation was linked to recognition by conformation-dependent CRP antibodies. Unmasking of the mAb 9C9-defined neoepitope in pCRP* correlated with the triggering of Fc{gamma}Rs, indicating that pCRP* is the major Fc{gamma}R-activating CRP conformation. The assay provides a novel, scalable approach to determine the molecular properties of CRP as a physiological ligand of Fc{gamma}R-mediated bioactivities. Scope statementFc{gamma} receptors (Fc{gamma}Rs) are important immune regulators that come in different variants and combinations, making it difficult to predict which components will ultimately lead to immunological effector functions. Classical Fc{gamma}Rs are defined by their recognition of IgG-Fc, while other ligands, such as C-reactive protein (CRP), are often neglected. Circulating concentrations of CRP, an acute phase protein, are elevated during inflammatory responses. As a pattern recognition receptor, CRP binds to lysophosphatidylcholine expressed on the surface of dying cells and microbes in order to activate the complement system via C1q. We have established a reporter cell assay platform that goes beyond ligand binding and takes a deeper look at the activation outcome(s) by CRP compared with IgG-Fc. This is the first comprehensive study defining CRP-responsive vs non-responsive Fc{gamma}Rs and investigating the interaction of Fc{gamma}Rs with CRP isoforms (pCRP/pCRP*/mCRP). We distinguish binding from receptor triggering using reporter cells stably expressing a chimeric Fc{gamma}R-CD3{zeta} chain, thereby defining the molecular requirements for Fc{gamma}R cross-linking by CRP. The assay provides a novel, sensitive and scalable approach to the properties of CRP as a ligand inducing Fc{gamma}R-mediated bioactivities.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Henning, A., Seer, J., Zeller, J., Peter, K., Thome, J., Kolb, P., Eisenhardt, S. U., Hoffmann, K., Hengel, H.. 2025-03-25. Human Fcγ-receptors selectively respond to C-reactive protein (CRP) isoforms. https://doi.org/10.1101/2025.03.23.644781

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

TFAM Dependent Mitochondrial Fitness Limits CD8⁺ T Cell Immunopathology and Sustains Protective Immunity during Viral Pneumonia

During respiratory virus infection, CD8 T cells kill infected cells and establish antigen-specific memory, but mechanisms regulating these functions remain incompletely understood. Here, we identify mitochondrial transcription factor A (TFAM)-dependent mitochondrial fitness as a regulator of CD8 T cell function during influenza infection. Human CD8 T cells exhibited an age-associated decline in TFAM expression and mitochondrial function. To model this physiologically relevant decline and determine its consequences for antiviral immunity, we generated CD8 T cell-specific TFAM-haploinsufficient mice. TFAM insufficiency disrupted mitochondrial integrity and bioenergetics and increased mitochondrial DNA and oxidative stress. During influenza infection, TFAM-insufficient CD8 T cells exhibited increased cytotoxic and inflammatory activity associated with lung immunopathology without improved viral control. This early phenotype was followed by loss of effector function, diminished antigen-specific responses, reduced protection following adoptive transfer, and impaired heterosubtypic recall immunity. Thus, TFAM-dependent mitochondrial fitness is a cell-intrinsic regulator that limits immunopathology while sustaining recall immunity.

immunology↗

Gasdermin E couples mitochondrial stress to STING-driven neuronal pyroptosis during Chandipura virus encephalitis

Neurotropic RNA viruses are major causes of fatal encephalitis worldwide, yet how infected neurons transition from antiviral defense to inflammatory cell death is not well characterized. Chandipura virus (CHPV), an emerging neurotropic rhabdovirus, causes acute, rapidly progressive encephalitis with high case fatality in children, but the mechanisms underlying its neuropathogenesis remain poorly defined. Here, we demonstrate that CHPV suppresses canonical RNA virus sensing early but subsequently switches to a mitochondria-driven innate immune program that culminates in inflammatory cell death. Early infection of neuronal cells with CHPV was marked by reduced levels of the mitochondrial antiviral adaptor protein, MAVS and attenuation of type I and III interferon responses. As infection progressed, mitochondrial dysfunction promoted accumulation of mtROS, mitochondrial accumulation of cleaved GSDME and cytosolic mtDNA release, triggering STING activation, which coincided with robust neuroinflammation and pyroptotic cell death. Pharmacological inhibition or genetic silencing of STING markedly attenuated inflammatory signaling, prevented pyroptotic membrane rupture and protected neurons from cell death without significantly affecting viral replication. In contrast, GSDME depletion reduced both viral replication and neuronal death. Notably, GSDME depletion markedly attenuated STING phosphorylation, while STING depletion also reduced GSDME activation, revealing functional coupling between these pathways during CHPV-induced neuronal injury. Collectively, our findings identify a mitochondria-GSDME-STING axis linking early immune evasion to neuroinflammation during CHPV infection, revealing a previously unrecognized mechanism of inflammatory neuronal death in viral encephalitis and highlighting STING as a potential therapeutic target in certain CNS viral infections.

immunology↗

Mutanome-guided immunopeptidomics of blood plasma for neoepitope detection in solid tumors is constrained by cfDNA variant calling sensitivity and MS detection limits

Introduction: Neoepitopes form the basis of tumor-specific immune responses. Tissue biopsy, the primary source for neoepitope detection, is limited and invasive. Therefore, we aimed to identify neoepitopes by mutanome-guided immunopeptidomics from plasma of cancer patients. Methods: Mass spectrometry (MS) data analysis of HLA ligands from plasma (n = 4) was guided by patient-specific mutanomes of cell-free DNA (cfDNA) from plasma or tumor genomic DNA (tgDNA) from tissue. Matched tumor tissue and healthy donor plasma served as controls. Neoepitopes were validated with synthetic peptides, and immunogenicity was assessed using IFN-gamma ELISpot and intracellular cytokine staining. Results: Wild-type immunopeptidomes from tissue and plasma overlapped by 58%, with 91% of plasma HLA ligands rediscovered in tissue. 13 out of 15 tumor-associated HLA ligands detected in plasma were rediscovered in the matching tissue. However, no neoepitopes in plasma were identified by immunopeptidomics guided by cfDNA mutanomes, likely reflecting the limited overlap between cfDNA and tgDNA mutanomes (15%). Using the tgDNA mutanome as a complementary reference, two neoepitopes were detected in one patient's plasma, albeit at the MS detection limit. Both neoepitopes were also discovered in tissue, along with three tissue-exclusive neoepitopes. Two tissue-exclusive neoepitopes induced antigen-specific T cell responses in healthy donor PBMCs. Conclusion: In summary, plasma immunopeptidomics enables profiling of HLA ligands from wild-type proteins, including TAAs. In principle, neoepitope detection from plasma at the peptide level is feasible, but tissue remains the gold standard for variant calling and neoepitope identification. Improved detection methods may enable minimally invasive approaches in the future.

immunology↗